{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:58:39Z","timestamp":1787500719920,"version":"build-2736575974"},"reference-count":107,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Despite advancements in treatment for B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL) in recent decades, many patients still relapse or are refractory to treatment, which represents a high unmet medical need. Novel CD20\u2009\u00d7\u2009CD3 T\u2010cell\u2013engaging bispecific antibodies (bsAbs) have created a new paradigm for the treatment of B\u2010NHL. Pivotal studies of four CD20\u2009\u00d7\u2009CD3 bsAbs, mosunetuzumab, glofitamab, epcoritamab, and odronextamab, as monotherapy, have demonstrated robust responses with generally manageable safety profiles in patients with relapsed or refractory follicular lymphoma and diffuse large B\u2010cell lymphoma after \u2265\u20092 lines of systemic therapy. These agents have presented unique challenges (e.g., cytokine release syndrome [CRS]), which have required different strategies to overcome. This review provides a comprehensive overview of the clinical development of these four CD20\u2009\u00d7\u2009CD3 bsAbs that have been investigated for the treatment of B\u2010NHL, with a specific focus on translational assessments to select starting doses in first\u2010in\u2010human studies, management of CRS, application of modeling and simulation approaches to aid dose escalation and optimization\/selection, and strategies used in the design of phase I\u2013III clinical trials. By highlighting learnings and experiences from these four bsAbs assessed, which have not been summarized collectively elsewhere, we aim to promote more efficient study design for novel bsAbs in B\u2010NHL in the future.<\/jats:p>","DOI":"10.1111\/cts.70250","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T12:40:03Z","timestamp":1749127203000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["<scp>CD20<\/scp>\n                    \u00d7\n                    <scp>CD3<\/scp>\n                    Bispecific Antibodies in B\u2010NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-9602","authenticated-orcid":false,"given":"Min","family":"Zhu","sequence":"first","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2286-0920","authenticated-orcid":false,"given":"Xiaowen","family":"Guan","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-1959","authenticated-orcid":false,"given":"Samit","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5968-3323","authenticated-orcid":false,"given":"Erik","family":"Welf","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"},{"name":"Orion Corporation  Espoo Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6282-1670","authenticated-orcid":false,"given":"John D.","family":"Davis","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_10_3_1","unstructured":"Leukemia & Lymphoma Society \u201cNHL Subtypes \u201dhttps:\/\/www.lls.org\/lymphoma\/non\u2010hodgkin\u2010lymphoma\/nhl\u2010subtypes."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01113-2"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02775-9"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01011-z"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179818"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2239"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00166-2"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2321648"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00905-y"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184550"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3361"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3308"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12582"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15092"},{"key":"e_1_2_10_21_1","unstructured":"EMA \u201cGuideline on Strategies to Identify and Mitigate Risks for First\u2010In\u2010Human and Early Clinical Trials With Investigational Medicinal Products \u201d(2017) https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010strategies\u2010identify\u2010and\u2010mitigate\u2010risks\u2010first\u2010human\u2010and\u2010early\u2010clinical\u2010trials\u2010investigational\u2010medicinal\u2010products\u2010revision\u20101_en.pdf."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3439"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20033"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0455"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027044"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005954"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19455"},{"key":"e_1_2_10_28_1","unstructured":"ASCO Publications \u201cGenentech Protocol GO29781 Version 12 \u201d(2021) https:\/\/ascopubs.org\/action\/downloadSupplement?doi=10.1200%2FJCO.23.02329&file=protocol_JCO.23.02329.pdf."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"e_1_2_10_30_1","unstructured":"FDA \u201cLunsumio US PI \u201d(2022) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761263s000lbl.pdf."},{"key":"e_1_2_10_31_1","unstructured":"FDA CDER \u201cBLA 761263 Multi\u2010Disciplinary Review and Evaluation \u201d(2022) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761263Orig1s000MultidisciplineR.pdf."},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.12.019"},{"key":"e_1_2_10_33_1","unstructured":"FDA \u201cColumvi US PI \u201d(2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761309s000lbl.pdf."},{"key":"e_1_2_10_34_1","unstructured":"FDA CDER \u201cBLA 761309 Multi\u2010Disciplinary Review and Evaluation \u201d(2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761309Orig1s000MultidisciplineR.pdf."},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"e_1_2_10_36_1","unstructured":"ASCO Publications \u201cGenmab Protocol GCT3013\u201001 Version 9 \u201d(2020) https:\/\/ascopubs.org\/action\/downloadSupplement?doi=10.1200%2FJCO.22.01725&file=protocol_JCO.22.01725.pdf."},{"key":"e_1_2_10_37_1","unstructured":"FDA \u201cEpkinly US PI \u201d(2024) https:\/\/www.genmab\u2010pi.com\/prescribing\u2010information\/epkinly\u2010pi.pdf."},{"key":"e_1_2_10_38_1","unstructured":"FDA CDER \u201cBLA 761324 Multi\u2010Disciplinary Review and Evaluation \u201d(2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761324Orig1s000MultidisciplineR.pdf."},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13212"},{"key":"e_1_2_10_40_1","unstructured":"EMA \u201cOrdspono SmPC \u201dhttps:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/ordspono\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_41_1","unstructured":"National Center for Advancing Translational Sciences \u201cOdronextamab \u201d(2024) https:\/\/drugs.ncats.io\/substance\/8R5CM46UIO."},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135818"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009260"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022348"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0451-1"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158406"},{"key":"e_1_2_10_51_1","unstructured":"FDA CDER \u201cEstimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers: Guidance for Industry \u201d(2005) https:\/\/www.fda.gov\/media\/72309\/download."},{"key":"e_1_2_10_52_1","unstructured":"EMA \u201cTepkinly SmPC \u201d(2024) https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/tepkinly\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_53_1","unstructured":"EMA \u201cLunsumio SmPC \u201d(2024) https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/lunsumio\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_54_1","unstructured":"EMA \u201cColumvi SmPC \u201d(2024) https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/columvi\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-417144-2.00019-6"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1829337"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105616"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41231-019-0050-7"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0405-4"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9113"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106380"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146845"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158412"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.119_2630"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3445"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157729"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136311"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-846"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax8861"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1107"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-020-00145-7"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-2798"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158415"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.100943"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp079"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0592"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123961"},{"key":"e_1_2_10_80_1","unstructured":"Roche \u201cEuropean Commission Approves Roche's Fixed\u2010duration Columvi (Glofitamab) for People With Relapsed or Refractory Diffuse Large B\u2010Cell Lymphoma \u201d(2023) https:\/\/www.roche.com\/media\/releases\/med\u2010cor\u20102023\u201007\u201011."},{"key":"e_1_2_10_81_1","unstructured":"AbbVie \u201cAbbVie Announces European Commission Approval of TEPKINLY (Epcoritamab) for Adults With Relapsed or Refractory Diffuse Large B\u2010Cell Lymphoma \u201d(2023) https:\/\/news.abbvie.com\/2023\u201009\u201025\u2010AbbVie\u2010Announces\u2010European\u2010Commission\u2010Approval\u2010of\u2010TEPKINLY\u2010R\u2010epcoritamab\u2010for\u2010Adults\u2010with\u2010Relapsed\u2010or\u2010Refractory\u2010Diffuse\u2010Large\u2010B\u2010cell\u2010Lymphoma."},{"key":"e_1_2_10_82_1","unstructured":"AbbVie \u201cEuropean Commission Grants Second Indication Approval for TEPKINLY (Epcoritamab) for the Treatment of Adults With Relapsed\/Refractory Follicular Lymphoma \u201d(2024) https:\/\/news.abbvie.com\/2024\u201008\u201019\u2010European\u2010Commission\u2010Grants\u2010Second\u2010Indication\u2010Approval\u2010for\u2010TEPKINLY\u2010R\u2010epcoritamab\u2010for\u2010the\u2010Treatment\u2010of\u2010Adults\u2010with\u2010Relapsed\u2010Refractory\u2010Follicular\u2010Lymphoma."},{"key":"e_1_2_10_83_1","unstructured":"FDA \u201cFDA Grants Accelerated Approval to Epcoritamab\u2010bysp for Relapsed or Refractory Diffuse Large B\u2010Cell Lymphoma and High\u2010Grade B\u2010Cell Lymphoma \u201d(2023) https:\/\/www.fda.gov\/drugs\/drug\u2010approvals\u2010and\u2010databases\/fda\u2010grants\u2010accelerated\u2010approval\u2010epcoritamab\u2010bysp\u2010relapsed\u2010or\u2010refractory\u2010diffuse\u2010large\u2010b\u2010cell#:~:text=Approvals%20and%20Databases\u2010 FDA%20grants%20accelerated%20approval%20to%20epcoritamab%2Dbysp%20for%20relapsed%20or high%2Dgrade%20B%2Dcell%20lymphoma&text=On%20May%2019%2C%202023%2C%20the %2C%20Genmab%20US%2C%20Inc."},{"key":"e_1_2_10_84_1","unstructured":"FDA \u201cFDA Grants Accelerated Approval to Epcoritamab\u2010bysp for Relapsed or Refractory Follicular Lymphoma \u201d(2024) https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010epcoritamab\u2010bysp\u2010relapsed\u2010or\u2010refractory\u2010follicular\u2010lymphoma."},{"key":"e_1_2_10_85_1","unstructured":"Regeneron Pharmaceuticals \u201cOrdspono\u2122 (Odronextamab) Approved in the European Union for the Treatment of Relapsed\/Refractory Follicular Lymphoma and Diffuse Large B\u2010Cell Lymphoma \u201d(2024) https:\/\/investor.regeneron.com\/news\u2010releases\/news\u2010release\u2010details\/ordsponotm\u2010odronextamab\u2010approved\u2010european\u2010union\u2010treatment."},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123712"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2729"},{"key":"e_1_2_10_88_1","volume-title":"Circulating Tumor DNA Analysis Associates With PFS With Odronextamab Monotherapy in R\/R FL and DLBCL: Identification of MRD Status and High\u2010Risk Subgroups From the Phase 2 ELM\u20102 Study (Poster P1230)","author":"Tucker D.","year":"2024"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180675"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13501"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13073"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.038679"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13091"},{"key":"e_1_2_10_94_1","unstructured":"E. S.Welf M.Zhu J.Brouwer\u2010Visser et\u00a0al. \u201cA Mechanistic Model to Inform Step\u2010Up Dosing That Limits Cytokine Release Following Odronextamab Treatment for B\u2010Cell Lymphomas.\u201d"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0020"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.29245\/2578-3009\/2018\/2.1126"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.35"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.561"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v32.i1.30"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2006.01.010"},{"key":"e_1_2_10_104_1","unstructured":"FDA \u201cProject Optimus\u2014Reforming the Dose Optimization and Dose Selection Paradigm in Oncology \u201d(2024) https:\/\/www.fda.gov\/about\u2010fda\/oncology\u2010center\u2010excellence\/project\u2010optimus."},{"key":"e_1_2_10_105_1","unstructured":"FDA CDER \u201cOptimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases: Guidance for Industry \u201d(2024) https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/optimizing\u2010dosage\u2010human\u2010prescription\u2010drugs\u2010and\u2010biological\u2010products\u2010treatment\u2010oncologic\u2010diseases."},{"key":"e_1_2_10_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7099"},{"key":"e_1_2_10_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7086"},{"key":"e_1_2_10_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00989-w"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T09:37:03Z","timestamp":1750930623000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/cts.70250"],"URL":"https:\/\/doi.org\/10.1111\/cts.70250","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2025-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70250"}}